Active Recombinant Cynomolgus TP53 Protein
Cat.No. : | TP53-1162C |
Product Overview : | Recombinant Cynomolgus TP53(E3U906) (Met 1-Asp 393) was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
Source : | E. coli |
Species : | Cynomolgus |
Tag : | N/A |
Form : | Lyophilized from sterile 50 mM Tris, pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Molecular Mass : | The recombinant Cynomolgus p53 consisting of 393 amino acids and has a calculated molecular mass of 43.7 kDa. It migrates as an approximately 48 kDa band in SDS-PAGE under reducing conditions. |
Protein Length : | Met 1-Asp 393 |
Purity : | > 80 % as determined by SDS-PAGE |
Storage : | Samples are stable for up to twelve months from date of receipt at -20°C to -80°C Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Products Types
◆ Recombinant Protein | ||
TP53-2772H | Recombinant Human TP53 Protein, His-tagged | +Inquiry |
TP53-2548H | Recombinant Human TP53 protein(101-310 aa), N-MBP & C-His-tagged | +Inquiry |
TP53-2773H | Recombinant Human TP53 Protein, His-tagged | +Inquiry |
TP53-2771H | Recombinant Human TP53 Protein, His-tagged | +Inquiry |
TP53-4893H | Recombinant Human TP53 (Y220C) Protein, Myc/DDK-tagged | +Inquiry |
◆ Lysates | ||
TP53-860HCL | Recombinant Human TP53 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionYes, identifying TP53 mutations in families with a history of early-onset cancers can help identify individuals at high risk for cancer and guide screening and prevention strategies.
TP53 mutations are highly diverse, making it challenging to develop a one-size-fits-all therapy. Additionally, the p53 pathway is complex, and disrupting it can have unintended consequences.
Yes, TP53 mutation status can be a criterion for eligibility in specific clinical trials, especially those testing experimental treatments that may target the p53 pathway.
TP53 status can influence treatment decisions. For example, patients with TP53 mutations may require more aggressive treatment approaches or different chemotherapy regimens.
Currently, there are no specific targeted therapies approved solely for TP53-mutated cancers. However, research is ongoing to develop drugs that target the altered p53 pathway.
Customer Reviews (3)
Write a reviewBy actively engaging with researchers and understanding their needs, manufacturers can contribute significantly to the success and impact of research involving the TP53 protein.
This flexibility allows for tailored approaches and provides researchers with more options to study specific aspects of TP53 biology or its interactions with other molecules.
Manufacturers can provide comprehensive product information, including data on the functionality, stability, and handling of TP53 protein.
Ask a Question for All TP53 Products
Required fields are marked with *
My Review for All TP53 Products
Required fields are marked with *
Inquiry Basket